||EPS - Basic
||Market Cap (m)
|Health Care Equipment & Services
Real-Time news about Nestor Health. (London Stock Exchange): 0 recent articles
|miikke: Has a date been set for the Interim management statement?
Crossed my mind that if the deal doesn't materialise and the share price falls a lot it could then recover if the IMS was positive...but fall further if the IMS is less rosy.
|fishbournetrader: With every other company that I have been involved in which has had a bid the share price has risen to the bid price or higher. Whilst the 100p may not be a formal offer I am surprised the offer price has not risen higher then the current 95p. Any ideas why?|
|susiebe: From todays Digital look
'Nestor Healthcare is in the health care equipment & services sector and is currently trading at 59.00p per share. In the last year Nestor Healthcare's share price has ranged from 26.75p to 61.00p and brokers are currently rating this stock as 'strong buy'.'|
|cockneyrebel: share price rising on all sells - a big buyer lerking imo.
|gswredland: Thanks Killieboy. Maybe we share price is anticipating good results!|
|bubbleandleek: no news in regards of Nestor is bad news!!! anyone hearing anything out there?? share price coming under sig pressure on the lack of news flow......|
|nickcduk: djpreston - Ordinarily I would agree about the LSE demanding an announcement. But this is NSR. Don't you remember how badly they behaved when the mail ran the story about bidders pulling out. It took them a good few hours despite the share price being down 30-40%. Happy to proven wrong though. Hopefully with confirmation that a bidder is offering £1+!|
|nickcduk: I had noticed the share price ticking up nicely without much fanfare. Market conditions have calmed down somewhat from a couple of months ago. Wonder if debt is now more readily available for a bidder to return to the table. Fingers crossed we might actually get a happy ending.|
There is the offending article. Its pretty extensive so is probably true. Unnecessary scaremongering with the share price likely to fall back to 30p. NSR management need to be revamped if talks fail. They dragged on the last set of talks for an age and ended up with nothing. If the same happens again they should fall on their swords.|
|victorskulicz: Here are five shares that look interesting on a 12-month view, some of which I own as medium to long-term plays. Together they are a mix of 'growth' and 'recovery' stocks, with the consistent factor being an attractive risk/reward profile. I should add the caveat that each stock carries with it an aspect of speculation regarding likely events to deliver value, and so things could turn out differently. These shares are also prone to volatility but that should be a bonus if you know what you are doing.
Dana Petroleum (DNX)
An astute business model and strong oil prices have helped Dana graduate to the FTSE 250 from the small cap index and the business looks set for continued progress. Dana's risk/reward is attractive because it combines strong production assets, mainly in the North Sea, with attractive exploration at home and abroad. The company is at the early stages of a major drilling programme that has started successfully and offers the prospect of 20 wells in 2008 - across the UK, Norway and Egypt. A share price of £13.90 may look dear but reflects Dana's progress in recent years and the intrinsic value is supported at lower oil prices than the current $90 or more. In practice oil prices, and therefore Dana's shares, are likely to remain volatile and so if holding such a share you should be steeled for at movements of at least 20% to 30% up or down in the near term. However, such volatility has been a backdrop to Dana shares multiplying in value eight times since 2002.
Analysts look for pre-tax profit of £200m or better in 2008, implying a prospective P/E near 13 times relative to earnings growth over 30%. Operationally, Dana is at an exciting stage. The main risk for its shares is whether the speculative premium currently in oil prices, disappears, for example if the US slides into recession. But China and India appear to have their own momentum and oil supply issues continue to support prices. Despite the inherent volatility of oil, I feel comfortable holding this share in anticipation of further upside. See www.dana-petroleum.com.
This specialty pharmaceutical group has developed and acquired an interesting range of mass market products. It is best known for 'dissolve-in-the-mouth' polymer technologies that can replace gelatine pills, and you can learn more at www.meldexinternational.com. Both 'Over The Counter' and prescription products are involved, with over 80 patents granted and marketing alliances with various global healthcare companies. At present, its markets are mainly in Europe and the US.
Meldex is at an exciting stage of its development and a spate of recent news about new products and institutions buying in, caught traders' imaginations. The shares surged from about 40p to above 90p then plunged after an update omitted to provide trading figures. The volatility looks like typical stockmarket noise until a company proves its earning power. A share price retreat to a low 50p range attracted buyers and the current level of 60p, capitalising Meldex at £116m, is interesting on a 12-month view (and longer).
Break-even was achieved (on a normalised basis) during the first half of 2007; analysts project near £4m pre-tax profit for the year as a whole and near £10m in 2008 as commercialisation kicks in. With announcements hinting at further commercial progress in the New Year and beyond, Meldex is an interesting share for 2008. Pharmaceuticals may also come back into stockmarket fashion, should consumer businesses be hit by slowdown. I own a shareholding.
Shares in this UK motor trader appear to have found a current support level at 105p after halving from 220p amid fears about consumer spending. I have recently noted how the directors have bought a substantial number of shares at higher prices than 108p, including the operations director and finance director - and they should be in good positions to judge the business. The concerted buying continues, with several directors adding on Christmas Eve at about 105p. Manifestly, they believe stockmarket pessimism is overdone, and it will be interesting to see how Lookers shares trend this year - as a test of whether you should take more notice of company directors or financial traders. Lookers is a fine business, strategically and operationally. See www.lookers.co.uk for more information.
A main risk with following the directors is whether their perspective is affected by being involved in the near-term issues of the business, which look positive, whereas the stockmarket senses the medium-term inevitability of the business cycle biting.
Cars represent 'discretionary spending' i.e. what can quite easily be avoided relative to essentials such as food. It is currently hard to be precise about what effect the ongoing credit crunch will have on personal also corporate spending, although the de-rating of some cyclical shares has already been brutal.
Aided by close relations with manufacturing partners and a decentralised approach, Lookers achieved 6% like-for-like sales growth in the first half of 2007 against 2% for the wider market. The interim dividend rose 23% and the directors are piling in before Lookers enters its closed period ahead of its preliminary results.
Taking a cautious view, if Lookers' profits remain flat in 2008, its shares now trade on a forward P/E of about 10 times. If the company can get anywhere near brokers' forecasts of £35m pre-tax profit then the P/E drops into single figures. There is uncertainty but in a portfolio context it may be worth engaging it, offsetting the risks via shares in unrelated industries.
Superscape Group (SPS)
At 8p currently, shares in the mobile games publisher appear to stand a fair chance of achieving upside, in relation to better trading and/or a takeover bid. The main risk is a consumer slowdown in the US where the now Californian-based business focuses its efforts.
Since achieving the number five position in the US mobile games publishers' league, Superscape has received an approach "that may or may not lead to a recommended cash offer". This would need to be pitched much higher than the current market value of £16m (including about £5m balance sheet cash) if the business is genuinely at a turning point given that institutions have waited nearly three years after a rights issue and placing at 38p. Mobile games publishing can be fickle, however, and intense competition means no guarantee of a growth business.
Although Superscape has yet to prove it is consistently cash-generative, it made a gross profit of £5.4m in the six months to the end of July 2007, so there is value for an acquirer after stripping out costs, in addition to tax losses to exploit.
Hence at about 8p, the risk/reward profile is interesting. Even if the business fails to sparkle, this kind of level ought to provide support for a bid, while the growing momentum of games publishing and distribution arrangements currently points to useful upside. The progression of trading updates will be influential although these can vary in the near term. I own a shareholding.
GCM Resources (GCM)
Formerly Asia Energy also Global Coal Management, Aim-listed GCM may be poised for government approval to mine a substantial coal deposit in Bangladesh. As is frequently the case with 'resources nationalism' in developing countries, the project went on the back burner in 2006 after agitators whipped up opposition. But Bangladesh has a serious energy problem with relentless power cuts and the Asian Development Bank is pushing for the mine to go ahead; and GCM has worked steadily to build a consensus. There is a fair chance GCM's scheme of development could be approved sometime during 2008 and the shares re-rate from 98p currently.
This is not a 'blue sky' gamble; the current share price has financial backing. At the end of June the company had nearly £17m balance sheet cash and a portfolio of investments that it has been successfully making while the management awaits approval of its mine development plan. Intrinsically, this limits downside risk to a few pence per share, with the stockmarket unwilling to ascribe much value to the intended Bangladesh coal mine.
The chairman and a non-executive director recently added to their shareholdings, just above 100p, presumably because they believe terms can be agreed with the government of Bangladesh. This is the kind of mining play where governments can keep tripping up foreign investors, but Bangladesh cannot mine the resource independently and GCM has an existing contract backed by international law. I own a shareholding.
This article is for information and discussion purposes only and does not form a recommendation to invest or otherwise. The value of an investment may fall. The investments referred to in this article may not be suitable for all investors, and if in doubt, an investor should seek advice from a qualified investment adviser.|
Nestor Healthcare share price data is direct from the London Stock Exchange